Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of KPL-404 in healthy volunteers
NCT04497662Phase 1Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of Abiprubart in rheumatoid arthritis (RA) and Sjögren's syndrome (3 arms), sponsored by Kiniksa Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events following IV dosing and Treatment-Emergent Adverse Events following SC dosing. Started Oct 2019; status: completed.
02
Drugs
Abiprubart
03
Conditions
rheumatoid arthritis (RA)Sjögren's syndrome
Beyond the preview
Go deeper on NCT04497662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497662.